MEMSCAP (NYSE Euronext: MEMS), the leading provider of innovative solutions based on MEMS (micro-electro-mechanical systems) technology and CARMAT, a Company specialized in the elaboration of biomaterials and advanced technologies applied to the field of artificial heart, today announce a partnership in the frame of development and industrialization of the first fully implantable artificial heart.
For MEMSCAP, this partnership confirms its major presence in the biomedical sector, through revolutionary products enhancing human lives. For CARMAT, this partnership, which benefits from MEMSCAP' experience and technologies, allows to realize spectacular progress in the development and industrialization of implantable artificial heart, thus contributing to save thousands of human lives. The CARMAT patented artificial heart prototype respects the biocompatibility criteria enabling its implantation in the human body. Its features are similar to a biological heart, both on the physiological and the anatomy levels.
The system, composed from an implantable part, a portable part as well as external devices supplying power and assuring its control and monitoring, integrates MEMSCAP sensors to automatically regulate cardiac output and frequency in function of the patient physiological needs, such as physical effort. "CARMAT has chosen to dedicate its activity to a major scientific challenge and to open new medical approaches. We are proud to help them realize those challenges and to offer an advanced system aiming to save multiple human lives », said Jan Hallenstvedt, General Manager of MEMSCAP' Standard Products Business Unit.
"MEMSCAP has been selected as we needed a partner having a strong experience in Microsystems capable of supplying us high quality products with extreme precision and very low time drift, showing strong robustness for many years », explained Marc Grimmé, Technical Director of CARMAT.